Hanall Biopharma (009420)

Seoul

Currency in KRW

27,100

-200(-0.73%)

Closed·07:29:59

Fair Value

Unlock Value

Day's Range

26,750

27,450

52 wk Range

24,000

52,000

009420 Income Statement

Featured here, the Income Statement (earnings report) for Hanall Biopharma, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Period Ending:

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

Total Revenues

aa.aa

88,602.27

101,594.44

109,995.42

134,909.84

138,943.7

Total Revenues Growth

aa.aa

-18.3%

+14.66%

+8.27%

+22.65%

+2.99%

Cost Of Revenues

aa.aa

38,027.08

41,363.62

48,119.77

59,870.21

65,738.03

Gross Profit

aa.aa

50,575.19

60,230.82

61,875.65

75,039.63

73,205.67

Gross Profit Growth

aa.aa

-19.31%

+19.09%

+2.73%

+21.27%

-2.44%

Gross Profit Margin %

aa.aa

57.08%

59.29%

56.25%

55.62%

52.69%

Other Operating Expenses, Total

aa.aa

44,640

50,131.7

60,369.86

73,296.2

72,975.19

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-2.09%	+12.3%	+20.42%	+21.41%	-0.44%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	9,316.28	10,462.42	16,498.47	23,944.95	19,992.61
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	34,137.43	38,450.23	42,646.79	48,038.62	51,723.77
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	541.03	605.75	584.09	669.45	660.34

Operating Income

aa.aa

5,935.19

10,099.12

1,505.79

1,743.43

230.47

Operating Income Growth

aa.aa

-65.27%

+70.16%

-85.09%

+15.78%

-86.78%

EBIT Margin %

aa.aa

6.7%

9.94%

1.37%

1.29%

0.17%

Net Interest Expenses

aa.aa

2,128.7

694.36

1,405.01

1,163.51

419.35

Net Interest Expenses Growth

aa.aa

+0.02%

-67.38%

+102.34%

-17.19%

-63.96%

Interest Expense, Total

aa.aa

-16.01

-25.48

-21.88

-63.86

-70.97

Interest And Investment Income

aa.aa

2,144.71

719.84

1,426.88

1,227.37

490.32

Other Non Operating Expenses, Total

aa.aa

11,220.51

-861.82

-874.02

-779.83

-711.9

EBT, Excl. Unusual Items

aa.aa

19,284.4

9,931.67

2,036.78

2,127.11

-62.07

Gain (Loss) On Sale Of Assets

aa.aa

-14.29

-1,052.14

16.99

-9.32

-452.56

Other Unusual Items, Total

aa.aa

-44.82

-36.72

EBT, Incl. Unusual Items

aa.aa

19,225.29

8,702.09

1,929.43

3,202.53

-183.2

EBT, Incl. Unusual Items Growth

aa.aa

+10.14%

-54.74%

-77.83%

+65.98%

-105.72%

EBT, Incl. Unusual Items Margin

aa.aa

21.7%

8.57%

1.75%

2.37%

-0.13%

Income Tax Expense

aa.aa

-539.21

-194.05

1,677.96

-306.08

1,621.65

Net Income to Company

aa.aa

19,764.5

8,896.14

251.47

3,508.61

-1,804.84

Minority Interest

aa.aa

Net Income

aa.aa

19,764.5

8,896.14

251.47

3,508.61

-1,804.84

Net Income Growth

aa.aa

+3.08%

-54.99%

-97.17%

+1,295.23%

-151.44%

Net Income Margin %

aa.aa

22.31%

8.76%

0.23%

2.6%

-1.3%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

19,764.5

8,896.14

251.47

3,508.61

-1,804.84

Basic EPS - Continuing Operations

aa.aa

386.19

173.74

4.95

69.21

-35.59

Basic EPS - Continuing Operations Growth

aa.aa

+3.08%

-55.01%

-97.15%

+1,298.63%

-151.42%

Diluted EPS - Continuing Operations

aa.aa

386.19

173.74

4.95

69.21

-35.59

Diluted EPS - Continuing Operations Growth

aa.aa

+3.08%

-55.01%

-97.15%

+1,298.63%

-151.42%

Basic Weighted Average Shares Outstanding

aa.aa

51.18

51.2

50.82

50.69

50.71

Diluted Weighted Average Shares Outstanding

aa.aa

51.18

51.2

50.82

50.69

50.71

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

8,829.41

12,823.98

4,558.44

4,990.38

3,350.99

EBITDA Growth

aa.aa

-55.42%

+45.24%

-64.45%

+9.48%

-32.85%

EBITDA Margin %

aa.aa

9.97%

12.62%

4.14%

3.7%

2.41%

EBIT

aa.aa

5,935.19

10,099.12

1,505.79

1,743.43

230.47

* In Millions of KRW (except for per share items)

NSE 30

5,135.68

+25.42

+0.50%

NSE All Share

139,863.52

+584.85

+0.42%

US 30

44,451.80

-9.5

-0.02%

US 500

6,392.30

+29.4

+0.46%

FTSE 100

9,136.82

-0.12

0.00%

DAX

24,072.85

-199.80

-0.82%

South Africa Top 40

90,781.37

-816.26

-0.89%

Market Movers

Name	Last	Chg. %	Vol.
Fidelitybk	21.050	+0.24%	81.12M
Guaranty Trust Holding	100.50	-1.42%	24.03M
Lafarge Africa	149.00	-1.32%	23.53M
Guinness Nigeria	117.05	+9.96%	13.30M
MTN Nigeria	472.00	+0.19%	5.89M
Dangote Cement	528.30	+3.67%	5.58M
Aradel Holdings	530.00	+3.09%	2.74M

Name	Last	Chg. %	Vol.
Wema Bank	22.00	+10.00%	22.15M
UAC Of Nigeria	80.30	+10.00%	1.59M
Guinness Nigeria	117.05	+9.96%	13.30M
Skyway Aviation Handling Company	90.05	+9.95%	2.66M
Mecure Industries	15.85	+9.69%	648.22K
Multverse	10.85	+9.60%	1.37M
Custodian Allied	36.00	+9.09%	2.41M

Name	Last	Chg. %	Vol.
Learn Africa	6.300	-10.00%	5.95M
Mansard Ins	11.700	-10.00%	12.84M
FTN Cocoa Processors PLC	5.67	-10.00%	11.29M
Initiates	13.50	-10.00%	4.51M
Ikeja	20.800	-9.96%	2.65M
Npfmcrfbk	3.080	-9.94%	6.74M
Nahco	99.100	-9.91%	3.20M

Trending Stocks

Name	Last	Chg. %	Vol.
Dangote Sugar	73.50	+3.30%	9.17M
Oando Plc	59.00	-0.51%	6.36M
Guaranty Trust Holding	100.50	-1.42%	24.03M
Access Holdings	27.90	+1.09%	41.95M
MTN Nigeria	472.00	+0.19%	5.89M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaaaa	528.30	+38.51%	731.75
A Aaaa Aaaaaa Aaa	5,450.00	+31.43%	7,162.94
Aaaaaaaaaaaaa A	67.00	+28.26%	85.93
Aa Aaaa	135.00	+20.66%	162.89

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Hanall Biopharma (009420)

009420 Income Statement

Trending Stocks